98%
921
2 minutes
20
This Statement is being simultaneously published in the journals Climacteric, Maturitas, Journal of Sexual Medicine, and Journal of Clinical Endocrinology and Metabolism on behalf of the International Menopause Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine, and The Endocrine Society, respectively. This Position Statement has been endorsed by the International Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine, The International Society for the Study of Women's Sexual Health, The North American Menopause Society, The Federacion Latinoamericana de Sociedades de Climaterio y Menopausia, The Royal College of Obstetricians and Gynaecologists, The International Society of Endocrinology, The Endocrine Society of Australia, and The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jsxm.2019.07.012 | DOI Listing |
J Trauma Stress
September 2025
Center of Alcohol and Substance Use Studies, Graduate School of Applied and Professional Psychology, Rutgers University-New Brunswick, Piscataway, New Jersey, USA.
Findable, Accessible, Interoperable, and Reusable (FAIR) data advances are becoming more common and more important across research fields given the large amount of research data in need of synthesis and application. Many novel methods improve the efficiency and accuracy of data reuse, combination, and synthesis, which is necessary given that there are over 500 published randomized controlled trials of posttraumatic stress disorder treatments in adults; however, these methods are still relatively new to the field of traumatic stress research. We provide a brief overview of relevant FAIR data efforts from other fields and within trauma health care and research; share examples of trauma-related FAIR data efforts to demonstrate recent advances and challenges; and suggest potential next steps to continue making trauma data more FAIR.
View Article and Find Full Text PDFBr J Cancer
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results.
Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer.
Ann Rheum Dis
September 2025
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Objectives: This study aims to evaluate the evolution of subchondral sacroiliac joint (SIJ) sclerosis from pregnancy to 12 months postpartum, and to explore preceding and concomitant magnetic resonance imaging (MRI) features, potentially indicating osteitis condensans ilii (OCI).
Methods: One hundred three first-time mothers were recruited for serial SIJ MRIs. MRI scans were performed at pregnancy weeks 20 and 32, and at 3, 6, and 12 months postpartum.
Bull Cancer
September 2025
Department of Pathology and Medical Biology, Cancer Genetics Laboratory, Gustave Roussy, Villejuif, France.
The effectiveness and tolerability of medicines can vary considerably from person to person, even at the same dose. This variation is influenced by many factors, including constitutional genetic characteristics. In fact, some people have genetic variations that are common and neutral in the population, known as polymorphisms, which can affect drug metabolism or make them more susceptible to certain adverse effects.
View Article and Find Full Text PDFJ Allergy Clin Immunol
September 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom; Frankland and Kay Allergy Centre, UK NIHR Imperial Biomedical Research Centre, United Kingdom.
Recent advancements in genomics and "omic" technologies have ushered in a transformative era referred to as personalized or precision medicine. This innovative approach considers the unique genetic profiles of individuals, along with a range of variability factors, to devise tailored disease treatments and prevention strategies that cater to the distinct needs of each patient. Although the terms personalized medicine and precision medicine are frequently utilized interchangeably, it is essential to delineate the subtle distinctions between them.
View Article and Find Full Text PDF